<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Diagnosis and treatment of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Lynnette K Nieman, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Deborah P Merke, MD, MS</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">André Lacroix, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Martin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 09, 2019.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia (CAH) [<a href="#rid1">1-3</a>]. This conversion is mediated by 21-hydroxylase and is defective due to mutations in the <em>CYP21A2</em> gene.</p><p>The diagnosis and treatment of nonclassic CAH (NCCAH) due to 21-hydroxylase deficiency are reviewed here. The genetics and clinical manifestations of the nonclassic form of 21-hydroxylase deficiency and the classic form of 21-hydroxylase deficiency are reviewed separately. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a> and  <a class="medical medical_review" href="/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>.)</p><p class="headingAnchor" id="H365213921"><span class="h1">BACKGROUND</span><span class="headingEndMark"> — </span>Congenital adrenal hyperplasias (CAHs) are autosomal recessive disorders; 21-hydroxylase deficiency due to mutations in the <em>CYP21A2 </em>gene accounts for approximately 95 percent of cases.</p><p class="bulletIndent1"><span class="glyph">●</span>The most severely affected individuals with classic CAH due to 21-hydroxylase deficiency present during the neonatal period and early infancy with adrenal insufficiency and salt wasting or in the first few years of life with virilization. Females have ambiguous genitalia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most individuals are identified through neonatal screening; the characteristic biochemical abnormality is a high serum concentration of 17-hydroxyprogesterone. Affected neonates have concentrations greater than 3500 ng/dL (105 nmol/L), with most exceeding 10,000 ng/dL (300 nmol/L).</p><p></p><p>Nonclassic CAH (NCCAH) is a less severe form of the disorder in which there is 20 to 50 percent 21-hydroxylase enzyme activity compared with 0 to 2 percent in the classic form. Salt wasting is absent, and affected females do not have ambiguous genitalia. The biochemical findings are less severe than those seen with classic 21-hydroxylase deficiency.</p><p class="bulletIndent1"><span class="glyph">●</span>NCCAH is more prevalent than classic CAH. It is one of the most common autosomal recessive diseases, and the frequency varies by ethnicity. Among the white populations, the prevalence of NCCAH may be as high as 1 in 1000 to 1 in 100, with the prevalence being even higher among Hispanics, Yugoslavs, and Ashkenazi Jews.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NCCAH presents later in life with signs of androgen excess. Clinical features in late childhood include premature pubarche, acne, and accelerated bone age; adolescent and adult females present with hirsutism (60 percent), oligomenorrhea (54 percent), and acne (33 percent) [<a href="#rid2">2,4-10</a>]. (See  <a class="medical medical_review" href="/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Approximately two-thirds of patients with nonclassic 21-hydroxylase deficiency carry a severe mutation. Therefore, patients pursuing fertility should consider genotyping. (See <a class="local">'Genetic testing'</a> below.)</p><p></p><p class="headingAnchor" id="H21370138"><span class="h1">WHO SHOULD BE TESTED?</span><span class="headingEndMark"> — </span>Unlike patients with classic 21-hydroxylase deficiency, who are identified either through neonatal screening by detecting very high levels of 17-hydroxyprogesterone or by clinical findings (ambiguous genitalia, salt wasting), most patients with the nonclassic form will <strong>not</strong> be identified by neonatal screening. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p>Therefore, testing for nonclassic 21-hydroxylase deficiency should be considered in children and adults with the typical clinical features of the disorder. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Clinical presentations'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children</strong> – Children with premature pubarche or accelerated growth velocity (crossing growth percentiles) with advanced bone age. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Children'</a> and  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Women</strong> – Women with oligomenorrhea and hyperandrogenism (acne and/or hirsutism) because the clinical presentation of the nonclassic form of congenital adrenal hyperplasia (NCCAH) can be indistinguishable from that of polycystic ovary syndrome (PCOS). (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Female reproduction'</a> and  <a class="medical medical_review" href="/d/html/7436.html" rel="external">"Clinical manifestations of polycystic ovary syndrome in adults"</a>.)</p><p></p><p class="bulletIndent1">The prevalence of NCCAH in women who present with apparent PCOS is variable, depending upon the population studied. Testing for NCCAH is most important in higher-risk groups including Mediterranean, Hispanic, and Ashkenazi Jewish women. Some experts suggest testing for NCCAH only in high-risk populations, but we suggest measuring a basal 17-hydroxyprogesterone in <strong>all</strong> women who present with a PCOS-type picture [<a href="#rid11">11</a>]. (See <a class="local">'Differential diagnosis'</a> below and  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Female reproduction'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Men</strong> – A subset of males with NCCAH present in childhood with premature pubarche, accelerated growth velocity, and advanced bone age; however, many males with NCCAH remain asymptomatic and are never diagnosed. Some men are identified because they are tested following the diagnosis of a family member. Although most men with the nonclassic form have normal testicular function and normal fertility, testicular adrenal rests and infertility have been reported in rare isolated case reports [<a href="#rid12">12</a>]. However, we do not suggest routine screening for NCCAH in men with infertility. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Men'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Others</strong> – Other indications for biochemical testing for NCCAH include a family history of CAH [<a href="#rid13">13</a>] and patients with adrenal incidentaloma or bilateral adrenal masses with a history consistent with NCCAH. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a> and  <a class="medical medical_review" href="/d/html/153.html" rel="external">"Evaluation and management of the adrenal incidentaloma"</a>.)</p><p></p><p class="headingAnchor" id="H21370150"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H151972333"><span class="h2">17-hydroxyprogesterone</span><span class="headingEndMark"> — </span>An early morning baseline 17-hydroxyprogesterone is a good screening test for nonclassic CAH and may obviate the need for an ACTH test.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children</strong>, a 17-hydroxyprogesterone level of &gt;200 ng/dL (6 nmol/L) taken at 8:00 AM has 92 to 98 percent sensitivity and specificity for the diagnosis of nonclassic 21-hydroxylase deficiency [<a href="#rid14">14-18</a>]. The early morning timing is critical because the 17-hydroxyprogesterone level falls rapidly during the course of the day. Results are interpreted as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A normal level of 17-hydroxyprogesterone for prepubertal children (less than 115 ng/dL [3.5 nmol/L])  (<a class="graphic graphic_table graphicRef75217" href="/d/graphic/75217.html" rel="external">table 1</a>) excludes NCCAH with approximately 95 percent confidence.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A slightly high level of 17-hydroxyprogesterone (between 115 and 200 ng/dL [4.1 to 6.0 nmol/L]) is atypical but consistent with premature adrenarche [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche"</a>.)</p><p></p><p class="bulletIndent2">The patient should be followed clinically to determine if further testing is indicated (ie, for evidence of progressive puberty or virilization). If the clinical picture suggests progressive bone age advancement or virilization, an <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> should be performed. (See  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A moderately elevated level of 17-hydroxyprogesterone (eg, between 200 and 1500 ng/dL [6.0 to 45 nmol/L]) suggests possible NCCAH. An <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> is recommended to confirm the diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A very elevated 17-hydroxyprogesterone level (&gt;1500 ng/dL [45 nmol/L]) is diagnostic of NCCAH.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>adult women</strong>, the diagnosis of NCCAH is strongly suggested by a basal 17-hydroxyprogesterone value greater than 200 ng/dL (6 nmol/L) and confirmed with an <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a>.</p><p></p><p class="bulletIndent1">For initial screening, a <strong>morning </strong>(7:30 to 8 AM) serum sample for 17-hydroxyprogesterone concentration should be obtained during the follicular phase of the menstrual cycle if the woman is cycling regularly. For women with amenorrhea or infrequent menses, the sample can be drawn on a random day.</p><p></p><p class="bulletIndent1">If the basal sample is &gt;200 ng/dL (6 nmol/L), a high-dose (250 mcg) <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a>, the gold standard for diagnosis, should then be performed. The response to ACTH is exaggerated in NCCAH, and a serum 17-hydroxyprogesterone value exceeding 1500 ng/dL (43 nmol/L) [<a href="#rid5">5,6</a>] confirms the diagnosis. Rarely, stimulated values at 60 minutes in affected patients range between 1000 ng/dL (30 nmol/L) and 1500 ng/dL (43 nmol/L) [<a href="#rid4">4</a>]. This range is inconclusive, and the diagnosis should be confirmed with genotyping of the CYP21A2 gene [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">When a lower post-ACTH cutoff for 17-hydroxyprogesterone (&gt;1000 ng/dL) is used, the false-positive rate is high. In a study of 21 women with a stimulated serum 17-hydroxyprogesterone &gt;1000 ng/dL (30 nmol/L), only 5 out of 21 cases had the diagnosis confirmed by 24-hour urinary steroid profiling and genotyping. Four others were heterozygotes, and 12 had no mutation. This observation supports our approach to diagnosis; a 17-hydroxyprogesterone &gt;1500 ng/dL (43 nmol/L) after ACTH stimulation confirms the diagnosis. For patients with equivocal results (values between 1000 ng/dL [30 nmol/L] and 1500 ng/dL [43 nmol/L]), we perform genotyping to distinguish between a heterozygote carrier and an affected patient [<a href="#rid20">20,21</a>]. A more detailed description of the <a class="drug drug_general" data-topicid="9298" href="/d/drug information/9298.html" rel="external">ACTH stimulation test</a> (for adrenal insufficiency) is found separately). (See  <a class="medical medical_review" href="/d/html/157.html" rel="external">"Diagnosis of adrenal insufficiency in adults", section on 'Standard high-dose ACTH stimulation test'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The biochemical criteria used for diagnosis in men are the same as those used for women. Adult men are typically asymptomatic but may be diagnosed during a family evaluation [<a href="#rid13">13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond infancy, there are no age-related differences in the diagnosis of NCCAH based upon high-dose (250 mcg) ACTH stimulation testing.</p><p></p><p>The biochemical findings in patients with classic 21-hydroxylase deficiency are more severe. Untreated patients with classic congenital adrenal hyperplasia (CAH) have basal 17-hydroxyprogesterone concentrations greater than 3500 ng/dL (105 nmol/L) [<a href="#rid1">1</a>], with most exceeding 10,000 ng/dL (300 nmol/L) [<a href="#rid3">3,4</a>]. (See  <a class="medical medical_review" href="/d/html/145.html" rel="external">"Clinical manifestations and diagnosis of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H638856260"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>Children with NCCAH present with premature pubarche, accelerated growth velocity, and advanced bone age. Therefore, other diagnostic considerations in children include causes of premature pubarche such as premature adrenarche, precocious puberty, and other forms of CAH. (See  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche"</a>.)</p><p>In adolescents and adult females, the clinical presentation of NCCAH can be indistinguishable from that of polycystic ovary syndrome (PCOS). However, PCOS is far more common than NCCAH; basal levels of 17-hydroxyprogesterone may overlap, but ACTH stimulation testing works well to distinguish between the two [<a href="#rid22">22</a>]. (See <a class="local">'17-hydroxyprogesterone'</a> above and  <a class="medical medical_review" href="/d/html/7385.html" rel="external">"Diagnosis of polycystic ovary syndrome in adults"</a>.)</p><p class="headingAnchor" id="H638856294"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Genetic testing is not considered to be a primary diagnostic tool for NCCAH. However, it may be used when biochemical results are borderline or when genetic counseling is needed prior to conception. (See <a class="local">'Heterozygote carriers'</a> below and  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Risk of classic CAH in offspring'</a>.)</p><p class="headingAnchor" id="H1308905221"><span class="h3">Compound heterozygotes</span><span class="headingEndMark"> — </span>Approximately two-thirds of patients with nonclassic 21-hydroxylase deficiency are compound heterozygotes and carry a severe and mild mutation on different alleles. Therefore, patients pursuing fertility should consider genotyping [<a href="#rid16">16,23</a>]. The overall risk of severe (classic) 21-hydroxylase deficiency in a child of a patient with the nonclassic form has been estimated at 2.5 percent, while the risk of nonclassic deficiency is approximately 15 percent [<a href="#rid24">24</a>]. Knowledge of the partner's genotype can help assess these risks. (See  <a class="medical medical_review" href="/d/html/144.html" rel="external">"Genetics and clinical presentation of nonclassic (late-onset) congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Risk of classic CAH in offspring'</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Heterozygote carriers</span><span class="headingEndMark"> — </span>If it is important to document the presence of a carrier state for genetic counseling, <em>CYP21A2</em> genotyping should be performed. Biochemical testing has been used to identify heterozygote carriers of NCCAH, but results may be misleading and do not correlate well with results of genotyping. ACTH-stimulated 17-hydroxyprogesterone levels may be exaggerated and even overlap with some nonclassic patients, but heterozygote carriers may also have adrenal androgen responses to ACTH that overlap the responses of normal subjects [<a href="#rid7">7,8</a>]. As an example, in one study of 31 heterozygote carriers, only five (16 percent) had a serum 17-hydroxyprogesterone value after ACTH stimulation greater than the peak value seen in 90 healthy control subjects (580 ng/dL [17.55 nmol/L]) [<a href="#rid8">8</a>].</p><p>There is no clear consensus as to whether heterozygote carriers are at increased risk of developing hyperandrogenic symptoms. In several studies of women with hirsutism, 8 to 13 percent were identified as carriers [<a href="#rid25">25-27</a>], similar to the rate seen in nonhirsute women in two of the studies [<a href="#rid26">26,27</a>]. However, no relative with a single mutation was clinically symptomatic in another study of 242 subjects [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H7"><span class="h1">APPROACH TO TREATMENT</span></p><p class="headingAnchor" id="H9"><span class="h2">Children</span><span class="headingEndMark"> — </span>We suggest the following approach for children with nonclassic congenital adrenal hyperplasia (NCCAH), which is largely consistent with the Endocrine Society Guidelines on congenital adrenal hyperplasia (CAH) [<a href="#rid28">28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoids should be administered to children with early-onset or rapid progression of pubarche (development of pubic hair) and/or accelerated growth velocity (crossing height percentiles) with bone maturation significantly advanced (two or more years advanced) to adversely affect adult height [<a href="#rid28">28</a>]. Premature pubarche is defined as the isolated appearance of sexual hair before the age of eight years in girls and nine years in boys. (See  <a class="medical medical_review" href="/d/html/5806.html" rel="external">"Premature adrenarche"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children, the glucocorticoid of choice is <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 10 to 15 mg/m<sup>2</sup> divided into three daily doses. Higher doses may have adverse effects on growth and result in Cushingoid features. (See  <a class="medical medical_review" href="/d/html/5800.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in infants and children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Asymptomatic children who are diagnosed genetically due to family genotyping studies do not require treatment [<a href="#rid29">29</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Premature pubarche without advanced bone maturation can be monitored every six months without treatment [<a href="#rid28">28</a>]. (See <a class="local">'Monitoring treatment'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment may be discontinued during early to mid-puberty for boys and two to three years postmenarche for girls [<a href="#rid30">30</a>]. In girls with persistent symptoms (such as menstrual irregularities or hirsutism), other treatment modalities (eg, oral contraceptives [OCs]) are usually preferred to avoid prolonged glucocorticoid use.</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Women</span></p><p class="bulletIndent1"><span class="glyph">●</span>Hirsutism and acne in women – We suggest combined estrogen-progestin OCs as first-line therapy for hyperandrogenic symptoms and management of oligomenorrhea. Antiandrogens can be added if the response to OCs is inadequate. Glucocorticoid therapy should only be used for those who do not respond to or cannot tolerate OC and antiandrogen therapies [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1">The main reason that OCs are first-line therapy for most women with NCCAH, is because hirsutism typically requires long-term therapy, and glucocorticoids have a number of potential risks and side effects. The choice of an OC is the same as for any woman with hirsutism (eg. women with polycystic ovary syndrome). (See  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women"</a>.)</p><p></p><p class="bulletIndent1">Exogenous glucocorticoids, which suppress hypothalamic corticotropin-releasing hormone (CRH) production and, therefore, pituitary corticotropin (ACTH) and adrenal androgen production, are used long term to manage hirsutism and maintain ovulatory cycles in women with <strong>classic</strong> 21-hydroxylase deficiency (see  <a class="medical medical_review" href="/d/html/136.html" rel="external">"Treatment of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults"</a>). They have also been investigated as a therapy for hirsutism in women with NCCAH. In two trials of glucocorticoid therapy in women with NCCAH (one randomized, one nonrandomized), <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> [<a href="#rid32">32</a>] and <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid33">33</a>] were more effective than an OC or an antiandrogen (<a class="drug drug_general" data-topicid="9295" href="/d/drug information/9295.html" rel="external">cyproterone acetate</a>), respectively, for suppressing serum adrenal androgen concentrations (dehydroepiandrosterone [DHEA] and DHEA sulfate [DHEAS]) but less effective for decreasing hirsutism scores.</p><p></p><p class="bulletIndent1">OCs, which suppress ovarian androgens, also suppress ACTH and adrenal androgens [<a href="#rid34">34-37</a>]. As noted, they appear to be more effective for hirsutism than glucocorticoids [<a href="#rid32">32,33</a>].</p><p></p><p class="bulletIndent1">Antiandrogens, such as <a class="drug drug_general" data-topicid="9943" href="/d/drug information/9943.html" rel="external">spironolactone</a>, are also effective, but we suggest against antiandrogen monotherapy because of their potential teratogenicity. In the United States, spironolactone is the most commonly used antiandrogen, while <a class="drug drug_general" data-topicid="9295" href="/d/drug information/9295.html" rel="external">cyproterone acetate</a> is typically used in other countries (not available in the United States). The management of hirsutism is reviewed in detail separately. (See  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Oligomenorrhea – If fertility is not desired, we suggest OC agents rather than glucocorticoid therapy for menstrual cycle management. Although glucocorticoids may restore ovulation and regular cycles, they do not provide contraception, and, as noted, they are associated with important risks and side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who cannot tolerate or take OCs or antiandrogen therapy, glucocorticoid therapy may be used for both hyperandrogenic symptoms and menstrual cycle management.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anovulatory infertility – We suggest glucocorticoid therapy as the initial treatment for ovulation induction in women with NCCAH [<a href="#rid38">38</a>]. <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">Clomiphene</a> citrate and other assisted reproduction techniques may be added if glucocorticoid therapy alone is ineffective [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">Dexamethasone</a> is not inactivated by placental 11-beta-hydroxysteroid dehydrogenase type 2 (fetal exposure occurs). Therefore, we suggest <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> for ovulation induction [<a href="#rid28">28</a>]. We typically start with prednisone 5 mg/day and add <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate if ovulation has not occurred with prednisone alone. Alternatively, the prednisone dose can be increased to 7.5 mg/day before adding clomiphene. The general management of anovulatory infertility is reviewed elsewhere. (See  <a class="medical medical_review" href="/d/html/7407.html" rel="external">"Overview of ovulation induction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Glucocorticoid therapy may be discontinued when an adult woman no longer seeks fertility. Hyperandrogenic symptoms may persist, however, and require ongoing therapy. We suggest stopping glucocorticoid therapy and switching to OCs in women being treated only for oligomenorrhea and/or hyperandrogenism. If glucocorticoids must be used (if other treatment options are not tolerated or contraindicated), <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.25 mg given once daily or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> 4 to 6 mg per day divided into two doses are suggested starting doses [<a href="#rid28">28,30</a>]. The lowest dose that ameliorates the sign or symptom being treated should be used.</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Men</span><span class="headingEndMark"> — </span>Treatment is <strong>not</strong> necessary for men unless there is oligospermia (in a man desiring fertility). For the rare patient requiring treatment, we suggest starting with <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> 0.25 mg given once daily or <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a> or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> 4 to 6 mg per day divided into two doses. While testicular adrenal rest tumors (TART) and infertility are common in men with classic CAH, they are thought to be very rare in men with NCCAH. Further studies are needed to evaluate fertility in men with NCCAH. (See  <a class="medical medical_review" href="/d/html/149.html" rel="external">"Genetics and clinical manifestations of classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency", section on 'Male reproduction'</a>.)</p><p class="headingAnchor" id="H217960968"><span class="h2">Stress-dose glucocorticoids</span><span class="headingEndMark"> — </span>Stress doses of glucocorticoids are not required for patients with NCCAH unless they have been receiving glucocorticoid therapy, which could suppress their hypothalamic-pituitary-adrenal axis [<a href="#rid2">2,40</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Monitoring treatment</span><span class="headingEndMark"> — </span>Standards have not been established for monitoring glucocorticoid therapy in adults with nonclassic 21-hydroxylase deficiency. In both children and women, concentrations of 17-hydroxyprogesterone, androstenedione, and testosterone should be measured in women, with the goal of normalizing androstenedione and testosterone levels. Adrenal androgen secretion should not be completely suppressed; suppressed levels of 17-hydroxyprogesterone generally indicate overtreatment, and elevation of 17-hydroxyprogesterone to two or three times the upper limit of normal is acceptable.</p><p>In children, one goal of treatment is normalization of height velocity; hence, growth charts should be maintained.</p><p>For women with classic CAH trying to conceive, monitoring progesterone is useful, and progesterone &lt;2 nmol/L (&lt;0.6 ng/mL) is associated with improved fertility in women with classic CAH [<a href="#rid41">41,42</a>]. It is unclear whether this is also true in women with NCCAH.</p><p>One should be alert to symptoms and signs of Cushing's syndrome. Patients should have measurements of bone mineral density periodically to look for bone loss [<a href="#rid43">43</a>]. The lowest dose that ameliorates symptoms should be used.</p><p class="headingAnchor" id="H1031141408"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/112671.html" rel="external">"Society guideline links: Classic and nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Nonclassic congenital adrenal hyperplasia (NCCAH) due to 21-hydroxylase deficiency is one of the most common autosomal recessive diseases, and the frequency varies by ethnicity. (See <a class="local">'Background'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Candidates for testing are described above. We suggest screening all women who present with oligomenorrhea and hyperandrogenism (suggestive of polycystic ovary syndrome [PCOS]) with a basal follicular phase 17-hydroxyprogesterone level as the clinical presentation of NCCAH in women is indistinguishable from PCOS. (See <a class="local">'Who should be tested?'</a> above.)</p><p></p><p class="bulletIndent1">A basal, morning serum 17-hydroxyprogesterone value (drawn in the early follicular phase in cycling women) greater than 200 ng/dL (6 nmol/L) strongly suggests the diagnosis. (See <a class="local">'17-hydroxyprogesterone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis is confirmed by an exaggerated serum 17-hydroxyprogesterone response to high-dose corticotropin (ACTH) (250 mcg) ≥1500 ng/dL (≥43 nmol/L). Rarely, stimulated values at 60 minutes in affected patients range between 1000 ng/dL (30 nmol/L) and 1500 ng/dL (43 nmol/L). This range is inconclusive, and the diagnosis should be confirmed with genotyping of the CYP21A2 gene. (See <a class="local">'17-hydroxyprogesterone'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest treating children with NCCAH with signs of hyperandrogenism and bone maturation significantly advanced to adversely affect adult height (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Children'</a> above). For children, we suggest <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a> 10 to 15 mg/m<sup>2</sup> divided into three daily doses. (See <a class="local">'Children'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with NCCAH receiving glucocorticoid therapy during childhood, we suggest discontinuing treatment during early to mid-puberty for boys and two to three years post-menarche for girls (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>) (see <a class="local">'Children'</a> above). In girls with persistent symptoms (such as menstrual irregularities or hirsutism), other treatment modalities (eg, oral contraceptives [OCs]) are usually preferred to avoid prolonged glucocorticoid use.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most adult women with nonclassic 21-hydroxylase deficiency who are not pursuing fertility, we suggest OCs as first-line therapy for hyperandrogenic symptoms (hirsutism). Antiandrogens can be added after six months if the response to OCs is inadequate (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Women'</a> above and  <a class="medical medical_review" href="/d/html/7444.html" rel="external">"Management of hirsutism in premenopausal women"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women who cannot tolerate or take OCs or antiandrogen therapy, glucocorticoid therapy may be used for both hyperandrogenic symptoms and menstrual cycle management. For sexually active women, <a class="drug drug_general" data-topicid="8535" href="/d/drug information/8535.html" rel="external">hydrocortisone</a>, <a class="drug drug_general" data-topicid="9809" href="/d/drug information/9809.html" rel="external">prednisone</a>, or <a class="drug drug_general" data-topicid="9808" href="/d/drug information/9808.html" rel="external">prednisolone</a> are suggested because <a class="drug drug_general" data-topicid="9334" href="/d/drug information/9334.html" rel="external">dexamethasone</a> crosses the placenta. (See <a class="local">'Women'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We also suggest OCs over glucocorticoids as first-line therapy for menstrual cycle management (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Women'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For women with nonclassic 21-hydroxylase deficiency with anovulatory cycles who desire fertility, we suggest glucocorticoids as initial therapy for ovulation induction (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). In women who do not ovulate with glucocorticoid therapy alone, we suggest adding <a class="drug drug_general" data-topicid="9281" href="/d/drug information/9281.html" rel="external">clomiphene</a> citrate (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Women'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We suggest not treating the majority of adult men with NCCAH with glucocorticoid therapy, as they are almost always asymptomatic. Testicular rests and infertility are very rare in this population (<a class="grade" href="https://medilib.ir/uptodate/show/grade_5" rel="external">Grade 2B</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Stress doses of glucocorticoids are not required for patients with NCCAH unless they have been receiving glucocorticoid therapy, which could suppress their hypothalamic-pituitary-adrenal axis. (See <a class="local">'Stress-dose glucocorticoids'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biochemical monitoring of therapy is described above. (See <a class="local">'Monitoring treatment'</a> above.)</p><p></p><p class="headingAnchor" id="H1643376850"><span class="h1">DISCLOSURE</span><span class="headingEndMark"> — </span>The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Witchel SF, Nayak S, Suda-Hartman M, Lee PA. Newborn screening for 21-hydroxylase deficiency: results of CYP21 molecular genetic analysis. J Pediatr 1997; 131:328.</a></li><li><a class="nounderline abstract_t">Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776.</a></li><li><a class="nounderline abstract_t">White PC, New MI, Dupont B. Congenital adrenal hyperplasia. (1). N Engl J Med 1987; 316:1519.</a></li><li><a class="nounderline abstract_t">New MI, Lorenzen F, Lerner AJ, et al. Genotyping steroid 21-hydroxylase deficiency: hormonal reference data. J Clin Endocrinol Metab 1983; 57:320.</a></li><li><a class="nounderline abstract_t">White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21:245.</a></li><li><a class="nounderline abstract_t">Azziz R, Dewailly D, Owerbach D. Clinical review 56: Nonclassic adrenal hyperplasia: current concepts. J Clin Endocrinol Metab 1994; 78:810.</a></li><li><a class="nounderline abstract_t">Gutai JP, Kowarski AA, Migeon CJ. The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia. J Pediatr 1977; 90:924.</a></li><li><a class="nounderline abstract_t">Fiet J, Gueux B, Gourmelen M, et al. Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1988; 66:659.</a></li><li><a class="nounderline abstract_t">Bachega TA, Brenlha EM, Billerbeck AE, et al. Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations. J Clin Endocrinol Metab 2002; 87:786.</a></li><li><a class="nounderline abstract_t">Admoni O, Israel S, Lavi I, et al. Hyperandrogenism in carriers of CYP21 mutations: the role of genotype. Clin Endocrinol (Oxf) 2006; 64:645.</a></li><li><a class="nounderline abstract_t">Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2013; 98:4565.</a></li><li><a class="nounderline abstract_t">Bonaccorsi AC, Adler I, Figueiredo JG. Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients. Fertil Steril 1987; 47:664.</a></li><li><a class="nounderline abstract_t">Nandagopal R, Sinaii N, Avila NA, et al. Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families. Eur J Endocrinol 2011; 164:977.</a></li><li><a class="nounderline abstract_t">Armengaud JB, Charkaluk ML, Trivin C, et al. Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche. J Clin Endocrinol Metab 2009; 94:2835.</a></li><li><a class="nounderline abstract_t">Rosenfield RL, Lucky AW. Acne, hirsutism, and alopecia in adolescent girls. Clinical expressions of androgen excess. Endocrinol Metab Clin North Am 1993; 22:507.</a></li><li><a class="nounderline abstract_t">Bidet M, Bellanné-Chantelot C, Galand-Portier MB, et al. Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members. J Clin Endocrinol Metab 2009; 94:1570.</a></li><li><a class="nounderline abstract_t">Escobar-Morreale HF, Sanchón R, San Millán JL. A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs. J Clin Endocrinol Metab 2008; 93:527.</a></li><li><a class="nounderline abstract_t">Livadas S, Dracopoulou M, Dastamani A, et al. The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene. Clin Endocrinol (Oxf) 2015; 82:543.</a></li><li><a class="nounderline abstract_t">Wilson RC, Mercado AB, Cheng KC, New MI. Steroid 21-hydroxylase deficiency: genotype may not predict phenotype. J Clin Endocrinol Metab 1995; 80:2322.</a></li><li><a class="nounderline abstract_t">Carmina E, Dewailly D, Escobar-Morreale HF, et al. Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women. Hum Reprod Update 2017; 23:580.</a></li><li><a class="nounderline abstract_t">Ambroziak U, Kępczyńska-Nyk A, Kuryłowicz A, et al. The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis. Clin Endocrinol (Oxf) 2016; 84:23.</a></li><li><a class="nounderline abstract_t">Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia. Fertil Steril 2010; 94:684.</a></li><li><a class="nounderline abstract_t">Finkielstain GP, Chen W, Mehta SP, et al. Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2011; 96:E161.</a></li><li><a class="nounderline abstract_t">Moran C, Azziz R, Weintrob N, et al. Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia. J Clin Endocrinol Metab 2006; 91:3451.</a></li><li><a class="nounderline abstract_t">Dolzan V, Prezelj J, Vidan-Jeras B, Breskvar K. Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status. Eur J Endocrinol 1999; 141:132.</a></li><li><a class="nounderline abstract_t">Glintborg D, Hermann AP, Brusgaard K, et al. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clin Endocrinol Metab 2005; 90:1347.</a></li><li><a class="nounderline abstract_t">Knochenhauer ES, Cortet-Rudelli C, Cunnigham RD, et al. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism. J Clin Endocrinol Metab 1997; 82:479.</a></li><li><a class="nounderline abstract_t">Speiser PW, Arlt W, Auchus RJ, et al. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018; 103:4043.</a></li><li><a class="nounderline abstract_t">Joint LWPES/ESPE CAH Working Group.. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002; 87:4048.</a></li><li><a class="nounderline abstract_t">Merke DP, Poppas DP. Management of adolescents with congenital adrenal hyperplasia. Lancet Diabetes Endocrinol 2013; 1:341.</a></li><li><a class="nounderline abstract_t">Martin KA, Chang RJ, Ehrmann DA, et al. Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93:1105.</a></li><li><a class="nounderline abstract_t">Spritzer P, Billaud L, Thalabard JC, et al. Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia. J Clin Endocrinol Metab 1990; 70:642.</a></li><li><a class="nounderline abstract_t">Frank-Raue K, Junga G, Raue F, et al. [Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate]. Klin Wochenschr 1990; 68:597.</a></li><li><a class="nounderline abstract_t">Fern M, Rose DP, Fern EB. Effect of oral contraceptives on plasma androgenic steroids and their precursors. Obstet Gynecol 1978; 51:541.</a></li><li><a class="nounderline abstract_t">Wiebe RH, Morris CV. Effect of an oral contraceptive on adrenal and ovarian androgenic steroids. Obstet Gynecol 1984; 63:12.</a></li><li><a class="nounderline abstract_t">Wild RA, Umstot ES, Andersen RN, Givens JR. Adrenal function in hirsutism. II. Effect of an oral contraceptive. J Clin Endocrinol Metab 1982; 54:676.</a></li><li><a class="nounderline abstract_t">Carr BR, Parker CR Jr, Madden JD, et al. Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment. J Clin Endocrinol Metab 1979; 49:346.</a></li><li><a class="nounderline abstract_t">Birnbaum MD, Rose LI. The partial adrenocortical hydroxylase deficiency syndrome in infertile women. Fertil Steril 1979; 32:536.</a></li><li><a class="nounderline abstract_t">Lo JC, Grumbach MM. Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia. Endocrinol Metab Clin North Am 2001; 30:207.</a></li><li><a class="nounderline abstract_t">Speiser PW. Nonclassic adrenal hyperplasia. Rev Endocr Metab Disord 2009; 10:77.</a></li><li><a class="nounderline abstract_t">Casteràs A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol (Oxf) 2009; 70:833.</a></li><li><a class="nounderline abstract_t">Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2013; 98:2645.</a></li><li><a class="nounderline abstract_t">Horrocks PM, London DR. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 1987; 27:635.</a></li></ol></div><div id="topicVersionRevision">Topic 147 Version 22.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9290628" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Newborn screening for 21-hydroxylase deficiency: results of CYP21 molecular genetic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930931" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3295543" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Congenital adrenal hyperplasia. (1).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6306039" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Genotyping steroid 21-hydroxylase deficiency: hormonal reference data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10857554" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8157702" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Clinical review 56: Nonclassic adrenal hyperplasia: current concepts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/192874" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : The detection of the heterozygous carrier for congenital virilizing adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2831244" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Comparison of basal and adrenocorticotropin-stimulated plasma 21-deoxycortisol and 17-hydroxyprogesterone values as biological markers of late-onset adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11836321" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Variable ACTH-stimulated 17-hydroxyprogesterone values in 21-hydroxylase deficiency carriers are not related to the different CYP21 gene mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16712666" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24151290" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3032693" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Male infertility due to congenital adrenal hyperplasia: testicular biopsy findings, hormonal evaluation, and therapeutic results in three patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21444649" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Phenotypic profiling of parents with cryptic nonclassic congenital adrenal hyperplasia: findings in 145 unrelated families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19454583" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Precocious pubarche: distinguishing late-onset congenital adrenal hyperplasia from premature adrenarche.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8243445" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acne, hirsutism, and alopecia in adolescent girls. Clinical expressions of androgen excess.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208730" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Clinical and molecular characterization of a cohort of 161 unrelated women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency and 330 family members.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18000084" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A prospective study of the prevalence of nonclassical congenital adrenal hyperplasia among women presenting with hyperandrogenic symptoms and signs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25041270" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The spectrum of clinical, hormonal and molecular findings in 280 individuals with nonclassical congenital adrenal hyperplasia caused by mutations of the CYP21A2 gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7629224" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Steroid 21-hydroxylase deficiency: genotype may not predict phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28582566" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Non-classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency revisited: an update with a special focus on adolescent and adult women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26331608" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The diagnosis of nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, based on serum basal or post-ACTH stimulation 17-hydroxyprogesterone, can lead to false-positive diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19726039" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase-deficient nonclassic adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20926536" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comprehensive genetic analysis of 182 unrelated families with congenital adrenal hyperplasia due to 21-hydroxylase deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16822826" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Reproductive outcome of women with 21-hydroxylase-deficient nonclassic adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10427156" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15598692" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9024240" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30272171" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12213842" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24622419" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Management of adolescents with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18252793" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Evaluation and treatment of hirsutism in premenopausal women: an endocrine society clinical practice guideline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2137832" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Cyproterone acetate versus hydrocortisone treatment in late-onset adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2142968" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : [Therapy of hirsutism in females with adrenal enzyme defects of steroid hormone biosynthesis: comparison of dexamethasone with cyproterone acetate].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/148599" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Effect of oral contraceptives on plasma androgenic steroids and their precursors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6228751" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Effect of an oral contraceptive on adrenal and ovarian androgenic steroids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6277979" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Adrenal function in hirsutism. II. Effect of an oral contraceptive.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/224073" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Plasma levels of adrenocorticotropin and cortisol in women receiving oral contraceptive steroid treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/227754" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The partial adrenocortical hydroxylase deficiency syndrome in infertile women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11344937" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Pregnancy outcomes in women with congenital virilizing adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18690539" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Nonclassic adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250265" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23837188" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Approach to the patient: the adult with congenital adrenal hyperplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2843311" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
